semaglutide alzheimer's Focus: After weight loss, may be next frontier for drugs like Ozempic GLP-1 Drug Fails to Quell

Observational studies and patient registries document thermoregulatory complaints in a subset of users, with symptom onset often coinciding with dose increases or early treatment weeks

One clinical trial, for instance, has led to a 14.7% mean weight reduction among those involved over the course of the 36-week trial

Additionally, individuals with NAFLD exhibit an impaired incretin effect independent of diabetes, displaying fasting hyperglucagonemia (8) and increased hepatic gluconeogenesis (9)

In those trials, semaglutide demonstrated average weight reductions of around 15% of body weight over 68 weeks when used alongside a reduced-calorie diet and increased physical activity

The study found that the risks of these adverse outcomes was similar with or without GLP-1 exposure during the first trimester